CL2020002993A1 - Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019) - Google Patents
Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)Info
- Publication number
- CL2020002993A1 CL2020002993A1 CL2020002993A CL2020002993A CL2020002993A1 CL 2020002993 A1 CL2020002993 A1 CL 2020002993A1 CL 2020002993 A CL2020002993 A CL 2020002993A CL 2020002993 A CL2020002993 A CL 2020002993A CL 2020002993 A1 CL2020002993 A1 CL 2020002993A1
- Authority
- CL
- Chile
- Prior art keywords
- atherosclerosis
- pcsk9
- ldl
- cardiovascular disease
- divisional application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
En el presente documento se proporcionan combinaciones de terapias que posibilitan el tratamiento, incluyendo la regresión, de la ateroesclerosis y/o la mejora de los resultados cardiovasculares. Descrito de modo general, esto incluye un primer agente reductor del LDL-C distinto de PCSK9 (tal como una estatina u otra terapia reductora de LDL-C distinta de PCSK9), combinado con una segunda terapia con inhibidor de PCSK9 (tal como un anticuerpo contra PCSK9 o anti-ARN). Se ha determinado que la aplicación de ambas terapias, a niveles adecuadamente elevadas a fin de reducir el nivel de LDL-C del sujeto hasta niveles muy bajos, durante un periodo de tiempo adecuado, proporciona un beneficio añadido de protección adicional frente a la ateroesclerosis y mejora los resultados cardiovasculares de un sujeto.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662421685P | 2016-11-14 | 2016-11-14 | |
US201762471874P | 2017-03-15 | 2017-03-15 | |
US201762515117P | 2017-06-05 | 2017-06-05 | |
US201762581244P | 2017-11-03 | 2017-11-03 | |
US201762584600P | 2017-11-10 | 2017-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002993A1 true CL2020002993A1 (es) | 2021-05-14 |
Family
ID=60484496
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001304A CL2019001304A1 (es) | 2016-11-14 | 2019-05-13 | Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica. |
CL2020002993A CL2020002993A1 (es) | 2016-11-14 | 2020-11-18 | Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001304A CL2019001304A1 (es) | 2016-11-14 | 2019-05-13 | Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20200368350A1 (es) |
EP (1) | EP3538149A2 (es) |
JP (2) | JP2019533715A (es) |
KR (1) | KR20190085963A (es) |
CN (1) | CN110234350A (es) |
AU (1) | AU2017356219A1 (es) |
BR (1) | BR112019009726A2 (es) |
CA (1) | CA3043700A1 (es) |
CL (2) | CL2019001304A1 (es) |
CO (1) | CO2019004814A2 (es) |
IL (1) | IL266579A (es) |
JO (1) | JOP20190112A1 (es) |
MA (1) | MA46758A (es) |
MX (1) | MX2019005627A (es) |
TN (1) | TN2019000156A1 (es) |
WO (1) | WO2018089912A2 (es) |
ZA (1) | ZA201902975B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016010927A1 (en) * | 2014-07-14 | 2016-01-21 | Amgen Inc. | Crystalline antibody formulations |
JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
CN113271931A (zh) * | 2018-07-31 | 2021-08-17 | 谭文 | 氨基甲酸酯β苯乙醇胺类似物增强胞内LDL胆固醇的清除及与他汀类药物联用的新用途 |
US20220245219A1 (en) * | 2019-07-19 | 2022-08-04 | Ebay Inc. | Sample Delta Monitoring |
CN112656792B (zh) * | 2021-01-26 | 2022-07-05 | 首都医科大学宣武医院 | 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2874149T3 (es) | 2006-05-11 | 2021-11-04 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión del gen PCSK9 |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
WO2010078536A1 (en) * | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
CN104651408A (zh) | 2009-06-15 | 2015-05-27 | 阿尔尼拉姆医药品有限公司 | 靶向pcsk9基因的脂质配制的dsrna |
AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
EA201390929A1 (ru) | 2010-12-22 | 2013-12-30 | Дженентек, Инк. | Антитела к pcsk9 и способы их применения |
KR20140006022A (ko) | 2011-02-11 | 2014-01-15 | 아이알엠 엘엘씨 | Pcsk9 길항제 |
JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
KR20220157516A (ko) * | 2014-03-17 | 2022-11-29 | 사노피 바이오테크놀로지 | 심혈관 위험을 감소시키는 방법 |
KR20170102983A (ko) * | 2015-01-09 | 2017-09-12 | 글로벌 게노믹스 그룹, 엘엘씨 | 죽상 경화성 관상 동맥 질환을 진단하기 위한 혈액 기반 바이오마커 |
-
2017
- 2017-06-16 JO JOP/2019/0112A patent/JOP20190112A1/ar unknown
- 2017-11-13 AU AU2017356219A patent/AU2017356219A1/en active Pending
- 2017-11-13 JP JP2019525021A patent/JP2019533715A/ja active Pending
- 2017-11-13 BR BR112019009726A patent/BR112019009726A2/pt unknown
- 2017-11-13 CN CN201780083280.9A patent/CN110234350A/zh active Pending
- 2017-11-13 WO PCT/US2017/061346 patent/WO2018089912A2/en unknown
- 2017-11-13 TN TNP/2019/000156A patent/TN2019000156A1/en unknown
- 2017-11-13 MX MX2019005627A patent/MX2019005627A/es unknown
- 2017-11-13 CA CA3043700A patent/CA3043700A1/en active Pending
- 2017-11-13 MA MA046758A patent/MA46758A/fr unknown
- 2017-11-13 US US16/348,653 patent/US20200368350A1/en active Pending
- 2017-11-13 EP EP17805364.1A patent/EP3538149A2/en active Pending
- 2017-11-13 KR KR1020197016872A patent/KR20190085963A/ko not_active IP Right Cessation
-
2019
- 2019-05-12 IL IL266579A patent/IL266579A/en unknown
- 2019-05-13 CO CONC2019/0004814A patent/CO2019004814A2/es unknown
- 2019-05-13 ZA ZA2019/02975A patent/ZA201902975B/en unknown
- 2019-05-13 CL CL2019001304A patent/CL2019001304A1/es unknown
-
2020
- 2020-11-18 CL CL2020002993A patent/CL2020002993A1/es unknown
-
2023
- 2023-02-13 JP JP2023019926A patent/JP2023071715A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JOP20190112A1 (ar) | 2019-05-14 |
BR112019009726A2 (pt) | 2019-08-13 |
CA3043700A1 (en) | 2018-05-17 |
MA46758A (fr) | 2019-09-18 |
WO2018089912A2 (en) | 2018-05-17 |
TN2019000156A1 (en) | 2020-10-05 |
AU2017356219A1 (en) | 2019-05-30 |
IL266579A (en) | 2019-07-31 |
JP2019533715A (ja) | 2019-11-21 |
EP3538149A2 (en) | 2019-09-18 |
KR20190085963A (ko) | 2019-07-19 |
JP2023071715A (ja) | 2023-05-23 |
ZA201902975B (en) | 2020-01-29 |
CL2019001304A1 (es) | 2019-09-23 |
CN110234350A (zh) | 2019-09-13 |
MX2019005627A (es) | 2019-10-14 |
CO2019004814A2 (es) | 2019-07-31 |
WO2018089912A3 (en) | 2018-06-21 |
US20200368350A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002993A1 (es) | Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019) | |
CL2017000080A1 (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
CL2016002372A1 (es) | Cenicriviroc para el tratamiento de la fibrosis. | |
AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
PE20211069A1 (es) | Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina | |
CL2020000384A1 (es) | Métodos para tratar y/o prevenir la enfermedad de injerto contra huésped y/o hemorragia alveolar difusa y/o enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas. | |
CL2018001258A1 (es) | Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2 | |
AR087790A1 (es) | Uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas | |
CL2017001964A1 (es) | Encapsulado de agentes activos de alta potencia. | |
CL2015002171A1 (es) | Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble. | |
CL2019002574A1 (es) | Moduladores de la expresión de pcsk9. | |
CO2017012645A2 (es) | Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo | |
PE20221421A1 (es) | METODO PARA EL TRATAMIENTO DE CANCER UTILIZANDO CELULA ADYUVANTE ARTIFICIAL (aAVC) | |
SV2016005308A (es) | Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
CL2021000892A1 (es) | Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica | |
AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
PE20220250A1 (es) | Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma | |
CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
MX2020004731A (es) | Terapias de combinacion de inhibidor ezh2. | |
CL2018002200A1 (es) | Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas. | |
EA201991160A1 (ru) | Средства комбинированной терапии атеросклероза, включая атеросклеротическое сердечно-сосудистое заболевание |